Tempus Pixel Prostate radiology solution

Tempus Pixel offers an AI-enabled solution that is trained with pathology data to detect suspicious lesions for clinically significant prostate cancer, and therefore can improve diagnostic accuracy and efficiency in aggressive prostate cancer detection and diagnosis. Pixel Prostate enhances prostate MRI interpretation by automating QC against PI-RADS v2.1 guidelines, gland segmentation, lesion detection and risk classification.

Prostate segmentation

Automatically segments the prostate zones, providing volume and dimensions¹

Lesion detection

Automatically detects suspicious lesions for clinically significant prostate cancer, and therefore can improve diagnostic accuracy of radiologists^1,2

Risk classification

Automatically classifies detected lesion as either high or moderate probability¹

Streamlined workflow

Automatic QC and reporting, as well as seamless integration with PACS and EMR¹

1. Tempus Pixel is FDA-cleared (K203744) and CE Marked. Prostate gland segmentation is powered by Quibim’s QP-Prostate® (K203582). QC against PI-RADS v2.1 guidelines is powered by Quibim’s QP-Prostate® (K203582) and QP-Prostate® CAD (K242683). Lesion detection and risk classification for clinically significant prostate cancer is powered by Quibim’s QP-Prostate® CAD (K242683). Arterys Inc is the manufacturer of Tempus Pixel. Quibim is the manufacturer of QP-Prostate® and QP-Prostate® CAD
2. Quibim data on file. J. Hillis and S. Mercaldo, "Quibim QP-Prostate CAD: Standalone Model Performance Assessment and Clinical Reader Performance Assessment: Clinical Study Report (Clinical Reader)," Mass General Brigham, QUI-C-002-REP-002, 2024.